Showing results (511-520 of 554) with videos related to
Sort By:
Pageof 56
The New England Journal of Medicine|February 20, 2019
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell CarcinomaBrian I Rini, Elizabeth R Plimack, Viktor Stus, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 7, 2023
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving NivolumabSuzanne L Topalian, Mario Sznol, David F McDermott, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 4, 2024
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trialN M Tannir, L Albigès, D F McDermott, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 6, 2024
Pooled Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone in Patients With Advanced MelanomaGeorgina V Long, James Larkin, Dirk Schadendorf, et al.The Lancet. Oncology|July 22, 2017
Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trialGeorgina V Long, Victoria Atkinson, Jonathan S Cebon, et al.Neuro-Oncology|April 21, 2021
Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204)Hussein A Tawbi, Peter A Forsyth, F Stephen Hodi, et al.The Lancet. Oncology|November 14, 2021
Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 studyHussein A Tawbi, Peter A Forsyth, F Stephen Hodi, et al.Cancer|October 5, 2023
The effect of neighborhood socioeconomic disadvantage on smoking status, quit attempts, and receipt of cessation support among adults with cancer: Results from nine ECOG-ACRIN Cancer Research Group trialsAngela Wangari Walter, Ju-Whei Lee, Joanna M Streck, et al.Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|July 6, 2023
Cigarette and Alternative Tobacco Product Use among Adult Cancer Survivors Enrolled in 9 ECOG-ACRIN Clinical TrialsJoanna M Streck, Ju-Whei Lee, Angela Wangari Walter, et al.The New England Journal of Medicine|February 20, 2019
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell CarcinomaRobert J Motzer, Konstantin Penkov, John Haanen, et al.Pageof 56